Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response?

Leuk Res. 2007 May;31(5):725-6. doi: 10.1016/j.leukres.2006.07.011. Epub 2006 Sep 15.

Authors

Vincenzo Pitini, Carmela Arrigo, Giuseppe Altavilla, Claudia Naro, Maria Righi

PMID: 16978696
DOI: 10.1016/j.leukres.2006.07.011

No abstract available

Publication types

Letter
Comment

MeSH terms

Apoptosis / drug effects*
Benzamides
Biomarkers
Eosinophils / drug effects*
Humans
Hypereosinophilic Syndrome / drug therapy*
Hypereosinophilic Syndrome / genetics
Hypereosinophilic Syndrome / metabolism
Imatinib Mesylate
Oncogene Proteins, Fusion / antagonists & inhibitors
Oncogene Proteins, Fusion / genetics
Oncogene Proteins, Fusion / metabolism
Piperazines / pharmacology*
Pyrimidines / pharmacology*
Receptor, Platelet-Derived Growth Factor alpha / antagonists & inhibitors
Receptor, Platelet-Derived Growth Factor alpha / genetics
Receptor, Platelet-Derived Growth Factor alpha / metabolism
mRNA Cleavage and Polyadenylation Factors / antagonists & inhibitors
mRNA Cleavage and Polyadenylation Factors / genetics
mRNA Cleavage and Polyadenylation Factors / metabolism

Substances

Benzamides
Biomarkers
Oncogene Proteins, Fusion
Piperazines
Pyrimidines
mRNA Cleavage and Polyadenylation Factors
Imatinib Mesylate
FIP1L1-PDGFRA fusion protein, human
Receptor, Platelet-Derived Growth Factor alpha